This review presents a critical evaluation of the role of Helicobacter pylori eradication in the management of peptic ulcer disease and non-ulcer dyspepsia. On current evidence, H. pylori eradication therapy seems likely to emerge as the most rational and cost-effective treatment for duodenal ulcer. The role of H. pylori eradication in the treatment of gastric ulcer and non-ulcer dyspepsia is unclear and requires further study. The emerging problem of antibiotic resistance in H. pylori is of major clinical importance and a prime cause of treatment failure. There is increasing evidence of a link between H.pylori and gastric cancer but it is premature to recommend large-scale eradication ofH. pylori as a valid strategy for the primary prevention of gastric cancer. The search continues for the ideal H. pylori eradication regimen.
Introduction
Since Warren and Marshall' first described the presence of Campylobacter-like organisms (now Helicobacter pylor2) in the human stomach, there has been phenomenal growth, which continues apace, in the volume of research literature on this microorganism. Several excellent general reviews on H. pylori are now available.3-6 Much recent interest, however, has centered on eradication of infection and this review specifically focuses on the therapies available and the clinical implications of eradication of H. pylori in peptic ulcer disease and non-ulcer dyspepsia. The evidence linking H. pylori and gastric cancer is also evaluated and the possible future role of H. pylori eradication in the primary prevention of gastric cancer is commented on.
Duodenal ulcer
The early observations by the Perth group7 that over 95% of duodenal ulcer patients had H. pylori infection and that the ulcer-healing agent colloidal bismuth subcitrate (CBS) was helicobactericidal provoked detailed re-evaluation of the role of bismuth and antibiotics in the treatment of duodenal ulcer disease. The fact that CBS was as effective as cimetidine or ranitidine in healing ulcers and somehow prevented ulcer relapse was already well known though ill understood.8-'0 Further interest was generated by early reports that furazolidonell and metronidazole,'2 both active against H. pylori, were as effective as H2 blockers in healing duodenal ulcer.
Our understanding of both the pathogenic role of H. pylori and of the mode of action ofbismuth in duodenal ulcer took a major step forward with publication of the landmark study of Coghlan et al. '3 In this single-blind trial, 66 patients were randomized to 6 weeks therapy with either CBS (DeNol) liquid (120 mg four times a day) or cimetidine (400 mg twice a day). Healing rates were similar in the two groups but over a 12 month follow-up period, ulcer relapse occurred in 79% of patients who remained H. pylori-positive after treatment compared with only 27% of those rendered H. pylori-negative. Histological gastritis was universal in the H. pylori-positive group but absent in the H. pylori-negative group. Only posttreatment H. pylori status was a significant predictor of ulcer relapse. In a reply to Coghlan's paper, Bianchi Porro and Lazzaroni'4 reported that they were unable to demonstrate H. pylori as a risk factor for duodenal ulcer recurrence but this was a small uncontrolled study with only a 6 month follow-up period during which one patient group continued on maintenance H2 blocker therapy that may have prevented ulcer relapse in H. pylori-positive patients. Furthermore, several subsequent studies'5120 have confirmed Coghlan's findings (Table I ).
In the study by Marshall et al.'6 100 H. pylori- 
Gastric ulcer
The association between H. pylori and peptic ulcer disease is stronger for duodenal than for gastric ulceration, in that virtually all duodenal ulcer patients have H. pylori-positive antral gastritis whereas about 30% of gastric ulcer patients are consistently H. pylori-negative.53 This finding coupled with the relative rarity of gastric compared with duodenal ulcer may account for the dearth of data on the effects ofH. pylori eradication in gastric ulcer.
In a study of 43 H. pylori-positive gastric ulcer patients randomized to receive 12 weeks treatment with either cimetidine or cimetidine plus cefixime in the last 2 weeks of therapy, Tatsutu et al. 54 found a similar healing rate in the two groups but a significantly lower recurrence rate at 12 weeks after finishing treatment in the dual therapy group; ulcer recurrence was, however, similar in the two groups at 24 weeks. Clearly, further studies of H. pylori eradication in gastric ulcer are needed which will incorporate large patient numbers, more effective eradication regimens and longer follow-up.
Socioeconomic impact of H. pylori eradication
The socioeconomic costs of peptic ulcer disease are very high. Firstly, peptic ulcer disease is a common condition which affects between 1 87 There are close parallels between the epidemiology ofH. pylori infection and gastric cancer. In areas of high prevalence for both gastric cancer and chronic gastritis, H. pylori infection is commonly acquired in childhood8889 whereas this is rare in countries such as North America with a low prevalence of gastric cancer.90 There is a strong association between gastric cancer risk and overcrowding in the home during childhood which might act by promoting the transmission ofH. pylori infection.9'
The frequency of H. pylori infection is increased in subjects from the lower social classes,92'93 who are also known to have a significantly higher prevalence of gastric cancer.94
Serological studies in rural China have shown a significant geographical correlation between gastric cancer mortality and the prevalence ofantibody to H. pylori.95 Furthermore, three recent independent case-control studies0498 found that infection with H. pylori was associated with an increased risk of gastric cancer. Parsonnet et al.97 found that persons seropositive for H. pylori were approximately three times more likely to develop gastric cancer in the ensuing years of follow-up than were control subjects matched for age, sex and race.
Nomura et al.98 also showed that as the level of antibody to H. pylori increased, there was a progressive increase in the risk of gastric cancer.
Vitamin C is both a potent antioxidant and an effective scavenger of nitrite, reducing it to nitric oxide and preventing N-nitroso compound formation in vitro99 and in vivo.'°0 N-nitroso compounds, formed by the interaction of nitrite and nitrosatable substrates, are powerful carcinogens which may well play a key role in the initiation of gastric cancer.'0' Gastric levels of vitamin C are substantially lower in patients with type B chronic gastritis.'021'04 Also, gastric secretory studies,102,'05 including detailed studies in a normal subject who inadvertently contracted H. pylori infection,'06 suggest that vitamin C is secreted by the stomach and that secretory capacity is impaired in the presence of gastritis. Hence, H. pylori infection may diminish the antioxidant and nitrite-scavenging capacity of gastric juice, thereby increasing the potential for N-nitroso compound formation in the stomach.
Acid secretion diminishes when type B gastritis extends to involve the body of the stomach.'07
Resultant hypochlorhydria leads to bacterial overgrowth and a rise in gastric juice nitrite due to reduction of salivary and dietary nitrate by nitratereductase active bacteria.'08"0 This in turn leads to increased levels of N-nitroso compounds in the gastric juice of some hypochlorhydric subjects compared with controls."0 Given this setting of enhanced potential for DNA damage, the increased cell turnover and mucosal instability inherent in chronic gastritis,"' and the known chronicity ofH. pylori infection, it is conceivable that a series of mutations could occur causing progressive mucosal dedifferentiation from complete to incomplete intestinal metaplasia" 2'13 and on to gastric dysplasia. 
